

#### Research evaluation

### REPORT ON THE RESEARCH UNIT:

Chemical and Biological Technologies for Health (UTCBS)

# UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Paris Descartes

Centre national de la recherche scientifique - CNRS

Institut national de la santé et de la recherche médicale - Inserm

## **EVALUATION CAMPAIGN 2017-2018**GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the experts committee<sup>2</sup>:

Jean Martinez, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>&</sup>lt;sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

<sup>&</sup>lt;sup>2</sup> The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Ycérés

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

#### **UNIT PRESENTATION**

Unit name: Chemical and Biological Technologies for Health

Unit acronym: UTCBS

Requested label: CNRS UMR 8258, Inserm U1022

**Application type**: Renewal

Current number: CNRS UMR 8258, Inserm U1022

Head of the unit

(2017-2018): Mr Daniel SCHERMAN

Project leader

(2019-2023): Ms Nathalie Mignet

Number of teams or themes: 3

#### **COMMITTEE MEMBERS**

Chair: Mr Jean Martinez, université de Montpellier

**Experts:** Ms Célia Bonnet, CNRS (representative of CoNRS)

Mr Olivier Boyron, université de Lyon 1

Mr Stephen HART, Institute of Child Health, London, United Kingdom

Mr Frédéric Lagarce, université d'Angers

Mr André Pelegrin, Inserm

Ms Khuloud AL-JAMAL, King's College, London, United Kingdom

**HCERES** scientific officer:

Mr Georges Massiot

#### Representatives of supervising institutions and bodies:

Mr Jean-Louis BEAUDEUX, université Paris Descartes

Mr Érick Dufourc, INC CNRS

Ms Christine Guillard, Inserm

Mr François Hırsch, Inserm

Mr Stephano Marullo, université Paris Descartes

Mr Marius Réglier, INC CNRS



#### INTRODUCTION

#### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The laboratory "Unités des Technologies Chimiques et Biologiques pour le Santé" (UTCBS-Laboratory Chemical and Biology Technologies for Health) was created in 2014 and recognised by four institutions, Inserm, CNRS, the Paris Descartes university, and Chimie ParisTech.

UTCBS is the continuation of the laboratory called "Chemical and Genetic Pharmacology and Bioimaging" created in 2004. UTCBS is composed of 4 teams (Team 1: SEISADE Team: "Synthèse, Électrochimie et Systèmes Analytiques pour le Diagnostic"; Team 2: VICT "Vectors for Molecular Imaging and Targeted Therapies"; Team 3: "Biotherapies by vectorization of nucleic acids"; Team 4: "Dynamique de l'Hématopoïèse: Aspects Fondamentaux et Translationnels de la modulation par les cytokines". Three teams (2,3,4) are located at the Faculty of Pharmacy of the university Paris Descartes, one team (1) is hosted by Chimie ParisTech. Due to the fact that Paris Descartes university and Chimie ParisTech do not belong to the same "Comue" (Communautés d'Universités), team 1, located at Chimie ParisTech, is not part anymore of the present contract. However, a close collaboration should be maintained with UTCBS through a convention between Paris Descartes university and PSL university for Chimie ParisTech.

#### MANAGEMENT TEAM

The UTCBS is headed by Mr Daniel Scherman, assisted by Mr Fethi Bedioui as vice-director. For the next contract, Ms Nathalie Mignet, is proposed as the new director.

#### **HCERES NOMENCLATURE**

ST4: chemistry.

#### SCIENTIFIC DOMAIN

The scientific goal of the UTCBS is to design and synthesize new diagnostics, therapeutic tools and agents focusing on innovative drug and nucleic acid delivery systems, as well as the characterization of biotherapeutics, including the identification of biomarkers and development of imaging agents. In 2014, at the beginning of the contract, a new team joined UTCBS dedicated to the investigation of the extra-erythroid role of the red blood cells erythropoietin (EPO) production.

#### **UNIT WORKFORCE**

Unit workforce	Number 30/06/2017	Number 01/01/2019	
Permanent staff			
Full professors and similar positions	9	6	
Assistant professors and similar positions	17	12	
Full time research directors (Directeurs de recherche) and similar positions	4	3	
Full time research associates (Chargés de recherche) and similar positions	4	2	
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	1	2	
High school teachers	0	0	



Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	12	11	
TOTAL permanent staff	47	35	
Non-permanent staff			
Non-permanent professors and associate professors, including emeritus	4		
Non-permanent full time scientists, including emeritus, post-docs	1		
Non-permanent supporting personnel	2		
PhD Students	18		
TOTAL non-permanent staff	25		
TOTAL unit	72		

#### GLOBAL ASSESSMENT OF THE UNIT

The scientific strategy of UTCBS is based on the development of multi-disciplinary research, associating chemists, physico-chemists, biologists and clinical researchers. The projects of UTCBS concern the development of technologies at the interface of chemistry and biology, directed to diagnostics, imaging agents, and advanced therapies, with the objective of medical applications, and commercialisation of their research, with high national and international visibility. Two of the three teams involved in the project are already complementary, and constitute a good mix of fundamental and applied science. Through one team, the UTCBS is also involved in a program aimed at studying the side-effects associated with the clinical use of recombinant EPO, and will bring an additional expertise to UTCBS. UTCBS will surely widen the visibility and the role of the School of Pharmacy in the field of life and health sciences. During the different meetings with Pls, researchers, technical staff, and students, that were informative, the expert committee could evaluate the involvement and the dynamism of the members of the unit, and no particular problem was raised apart from the lack of permanent staff including researchers and technicians. The new director who is proposed for the next contract was unanimously appreciated by all members of the committee. The meetings with the representatives of the university, CNRS, Inserm, Faculty of Pharmacy and Chimie ParisTech showed strong support to the unit from all of them.

The evaluation reports of Hceres are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions **Evaluation of research Evaluation of doctoral schools Evaluation of programmes** International evaluation and accreditation





